PODOMOUNT-Basket, a Phase II, Multicentre, Randomised, 2-arm Parallel-group, Double-blind, Placebo-controlled Basket Trial to Assess Safety, Tolerability, PK, and Efficacy of BI 764198 in Four Proteinuric Kidney Diseases

This study is open to adults with certain kidney conditions, including secondary focal segmental glomerulosclerosis (sFSGS), treatment-resistant primary minimal change disease (TR-pMCD), Alport Syndrome (AS), and treatment-resistant primary membranous nephropathy (TR-pMN). Adolescents with treatment-resistant primary MCD can also participate in this study. The purpose of this study is to find out whether a medicine called BI 764198 helps people with these kidney conditions.
Participants are put into 2 groups randomly, which means by chance. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine. Participants take a tablet once a day for 20 weeks. All participants also continue their standard medication for their kidney condition during the study. Participants have twice the chance of being placed in the BI 764198 group than in the placebo group.
Participants are in the study for about 7 months. During this time, they visit the study site 6 times and have 3 phone calls. Doctors regularly test the protein levels in participants' urine by collecting urine samples. They also check kidney function by taking blood samples. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date23 Mar 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07220083

/ RecruitingPhase 3

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled Trial to Assess the Effects of Oral TRPC6 Inhibitor BI 764198 Taken Over a 104 Week Treatment Period in Adult and Adolescent Participants With Primary Focal Segmental Glomerulosclerosis (pFSGS) or Genetic FSGS Related to TRPC6 Gene Variants

PODOMOUNT-pFSGS
This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 helps people with FSGS.
Participants are put into 2 groups randomly, which means by chance. Every participant has an equal chance of being in each group. One group takes BI 764198 tablets, and the other group takes placebo tablets. Placebo tablets look like BI 764198 tablets but do not contain any medicine.
Participants take a tablet once a day for up to 2 years. All participants also continue their standard medication for FSGS.
Participants are in the study for up to 2 years. During this time, they visit the study site about every 3 months. Participants regularly collect urine samples. This is done to check their kidneys. The results are compared between the two groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

Start Date16 Feb 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

NCT07308652

/ CompletedPhase 1

The Effect of Multiple Doses of Itraconazole on the Single-dose Pharmacokinetics of BI 764198 Following Oral Administration in Healthy Male Trial Participants (an Open-label, Non-randomised, Two-period, Fixed-sequence Design Study)

The purpose of this study is to find out whether a medicine called itraconazole changes the amount of another medicine called BI 764198 in the blood. Some people may take more than 1 medicine at a time. Therefore, it is important to understand how medicines influence each other. This study will help us learn more about how BI 764198 works.

Start Date09 Feb 2026

Sponsor / Collaborator

Boehringer Ingelheim GmbH

100 Clinical Results associated with Apecotrep

100 Translational Medicine associated with Apecotrep

100 Patents (Medical) associated with Apecotrep

Literatures (Medical) associated with Apecotrep

13 Aug 2026·EXPERT OPINION ON PHARMACOTHERAPY

Angiotensin system modulation in focal segmental glomerulosclerosis: pharmacological basis and clinical implications

Review

Author: Cipressa, Giulia ; La Spada, Alberto ; Santoro, Domenico ; Gembillo, Guido ; Casuscelli, Chiara ; Di Pietro, Ylenia ; Lo Re, Claudia

INTRODUCTION:

FSGS is a histological convergence point for biologically distinct conditions: primary immune-mediated, genetic, and secondary adaptive forms, each with its own pharmacological logic. ACE inhibitors and angiotensin receptor blockers have anchored its management for three decades on evidence drawn predominantly from non-FSGS populations.

AREAS COVERED:

Experimental and clinical literature from PubMed/MEDLINE, Embase, and Web of Science through 30 January 2026, covering angiotensin II-mediated podocyte injury, RAAS pharmacology across FSGS subtypes, and emerging strategies that extend or layer upon the RAAS backbone, including dual AT1/endothelin-A blockade, SGLT2 inhibition, and mineralocorticoid receptor antagonism, with additional podocyte-targeted and genotype-guided approaches.

EXPERT OPINION:

The clinical benefit of RAAS blockade appears to vary across FSGS subtypes. It likely targets a key pathogenic mechanism in secondary adaptive forms, while serving mainly as supportive antiproteinuric therapy in immune-mediated and genetic disease. Nonetheless, it remains a cornerstone of care.Emerging therapies, including dual AT1/endothelin-A antagonism (sparsentan) and podocyte-targeted approaches (apecotrep), show promising proteinuria reductions but have not yet demonstrated clear benefits on hard renal outcomes. Biomarker-driven strategies (e.g. anti-nephrin antibodies, APOL1 genotyping) may enable more tailored treatment, although their clinical impact remains to be established.

01 Feb 2026·LANCET

TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198

Article

Author: Kretzler, Matthias ; Prasad, Srinivasa ; Cross, Nicholas ; Gesualdo, Loreto ; Licarião Rocha, Fabia T ; Trachtman, Howard ; Retlich, Silke ; Kaufeld, Jessica ; Ye, Zhiming ; Meijers, Björn ; Lobmeyer, Maximilian T ; Chen, Qinkai ; Derebail, Vimal K ; Soleymanlou, Nima ; Ng, Monica Suet Ying ; Ji, Bo ; Workeneh, Biruh

BACKGROUND:

In focal segmental glomerulosclerosis (FSGS), transient receptor potential cation channel, subfamily C, member 6 (TRPC6) overactivity might cause podocyte loss and progressive kidney function decline. This exploratory study assessed the safety and efficacy of a novel once-daily oral selective TRPC6 inhibitor, BI 764198.

METHODS:

This multicentre phase 2, double-blind, placebo-controlled, randomised controlled trial assessed BI 764198 (20 mg, 40 mg, or 80 mg once daily) versus placebo over 12 weeks in participants aged 18-75 years with biopsy-confirmed primary FSGS (based on the absence of clinical evidence of secondary cause) or with a disease-causing TRPC6 variant. The study took place in 31 sites in ten countries, and random allocation was performed centrally in blocks in a 1:1:1:1 ratio and was stratified according to use of corticosteroids. Participants were receiving stable conservative and immunosuppressive therapy, with screening urine protein-creatinine ratio (UPCR) at 1·0 g/g or greater and estimated glomerular filtration rate at 30 mL/min per 1·73 m² or greater. The primary endpoint was the proportion of participants with proteinuria response (≥25% UPCR reduction from baseline) at week 12. Other key outcomes were safety and tolerability. The study was registered with ClinicalTrials.gov on Jan 27, 2022 (NCT05213624) and is complete as of Jan 3, 2025.

FINDINGS:

From March 10, 2022, to Sept 3, 2024, 139 participants were screened and 67 were randomly assigned to receive placebo or BI 764198 at doses of 20 mg, 40 mg, or 80 mg (five participants were randomly assigned in error and were not treated). 62 participants received treatment, two of whom had missing baseline or post-baseline UPCR measurements and were not included in the full analysis set. Overall, 37 participants (60%) were male and 25 participants (40%) were female; the mean age was 40·7 years (SD 12·6); and the majority of the trial cohort were White (39 [63%] of 62). Proteinuria responses were observed in eight (44%) of 18, two (14%) of 14, and six (43%) of 14 participants receiving BI 764198 20 mg, 40 mg, and 80 mg, respectively (16 [35%] of 46 for all BI 764198 doses) versus one (7%) of 14 receiving placebo; corresponding odds ratios (ORs) versus placebo were OR 10·0 (95% CI 1·6-118·1), 1·5 (0·2-19·5), and 6·0 (0·9-73·6) for the three doses of BI 764198, and 4·9 (1·0-48·8) for all doses combined. BI 764198 was well tolerated with no meaningful differences in adverse event frequencies across treatment arms; treatment-emergent adverse events were reported by 44 (71%) of 62 participants, with similar frequencies of adverse events observed in the placebo group (ten [71%] of 14) and BI 764198 groups (34 [71%] of 48).

INTERPRETATION:

BI 764198 lowered proteinuria and was well tolerated by participants in this trial. This is the first evidence of efficacy with a podocyte-targeted therapy in FSGS. Larger randomised controlled trials over longer treatment durations, enabling meaningful subgroup analyses, are planned to evaluate the safety and efficacy of BI 764198 treatment in FSGS and other conditions affected by podocytopathy.

FUNDING:

Boehringer Ingelheim.

01 Dec 2023·Kidney international reports

TRPC6 Inhibitor BI 764198 in Focal Segmental Glomerulosclerosis: Phase 2 Study Design

Article

Author: Desmond, Hailey E ; Kretzler, Matthias ; Choi, Wansuk ; Soleymanlou, Nima ; Manuel, Raymond C ; Trachtman, Howard

Focal segmental glomerulosclerosis (FSGS), a leading glomerular cause of kidney failure, is a histological pattern characterized by podocyte injury and depletion.1 FSGS is found in 20–30% of adults with nephrotic syndrome and up to 20% of patients receiving dialysis.2,S1 FSGS can be broadly categorized into four causative classifications: primary (idiopathic), secondary (adaptive), familial (genetic), and of unknown cause.1,3,S2 Depending on patient selection and region, genetic variants have been reported in up to 14% of individuals with adult-onset FSGS.

News (Medical) associated with Apecotrep

15 Jul 2026

·www.biospace.com

Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.

Strong U.S. demand and new product launches drive first-half sales in Human Pharma Net sales reach EUR 15.8 billion, led by JARDIANCE® and successful U.S. launches Positive Phase III data for survodutide and pipeline progress strengthen long-term outlook Boehringer Ingelheim reported continued sales growth in the first half of 2026, driven by strong growth in the U.S. due to increased demand for JARDIANCE® (empagliflozin) and successful new launches. Group net sales increased by 16.2%* to EUR 15.8 billion, with Human Pharma contributing EUR 13.1 billion and Animal Health EUR 2.6 billion. Shashank Deshpande, Chairman of the Board of Managing Directors and Head of Human Pharma, Boehringer Ingelheim said: “The strong uptake of our new products JASCAYD® and HERNEXEOS® show the value of the scientific innovation behind these medicines for patients, bringing real progress in areas with significant unmet medical need. In an era of accelerated medical discovery, where the boundaries of what is possible are continuously expanding, innovation-friendly environments such as the United States play a critical role in ensuring new therapies reach patients more rapidly.” Frank Hübler, Member of the Board of Managing Directors responsible for Finance, added: “Our business results show that, in Human Pharma and Animal Health, we successfully navigated a challenging macroeconomic environment and political uncertainties. We remain focused on delivering innovative medicines to patients and animals worldwide. Looking ahead, we need to direct our long-term investments to where they are closest to our growth markets and where they can create the best possible impact for patients. This also includes engaging with governments around the globe to create an environment that appropriately recognizes the value of innovative medicines and ensures patient access.” Human Pharma: Growth supported by key launches Human Pharma sales grew 20.1%* to EUR 13.1 billion, supported by the new product launches. Established products such as JARDIANCE® for the treatment of chronic kidney disease, type 2 diabetes and heart failure remained major growth drivers, contributing EUR 5.7 billion in net sales in the first half of the year. The positive development of JARDIANCE® was supported by a large and growing patient base, as well as changes in the U.S. pricing and reimbursement environment, which drove significant volume growth. This trend is in line with Boehringer’s commitment to ensuring continued patient access and affordability. Without the JARDIANCE® volume effect, the growth of the Human Pharma Business Unit in the first six months would have been in line with the overall pharma market. The company also saw a successful uptake of its most recent product launches, JASCAYD® (nerandomilast) and HERNEXEOS® (zongertinib), particularly in the U.S., as both medicines were able to gain significant traction thanks to the innovation-friendly climate in the U.S. but also in China and Japan. Streamlined processes as well as stronger incentives for innovation in these geographies paved the way for swiftly making these breakthrough medicines available to patients. JASCAYD®, for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), saw a strong uptake reflecting the urgent need for new treatment options in a disease area that has seen limited therapeutic progress for many years. Following approvals in the United States, China and Japan, as well as Thailand, the United Arab Emirates, the UK and Brazil, JASCAYD® is awaiting EU approval from the European Medicines Agency (EMA). HERNEXEOS®, an oral treatment for HER2-mutant advanced non-small cell lung cancer, marked the company’s successful re-entry into oncology after ten years with launches in the U.S., China and Japan. The company expects that HERNEXEOS® will be available for European patients only from 2028 after Phase III data becomes available. Boehringer continued to advance its late-stage pipeline programs during the first half of 2026, realizing significant progress in oncology and cardio-renal-metabolic diseases. Positive Phase III data for survodutide demonstrated the medicine’s potential to address metabolic and liver health in addition to overweight and obesity. Progress with a next-generation triple agonist underlines Boehringer’s ambition to build a broad obesity and metabolic health portfolio. At the same time, Boehringer Ingelheim initiated three Phase III oncology trials, reinforcing its goal to expand precision cancer care. The company also advanced key assets such as obrixtamig, an experimental cancer immunotherapy, and apecotrep, an investigational drug targeting kidney disease. Research momentum also continued to be strong, with five new compounds entering clinical trials. The Boehringer Human Pharma R&D pipeline spans around 80 projects. Animal Health: Focus on new launches and emerging disease outbreaks response The Animal Health business reported net sales of EUR 2.6 billion in the first six months of 2026, a 0.4%* increase compared to the previous year. The performance reflected a modestly growing animal health market, with increased consumer price sensitivity and fewer veterinary visits in several countries. The company continues to execute its 2026 launch plan, including LENZELTA®, a new vaccine that advances mastitis prevention in dairy cows and has launched in several EU countries, and Eko Vet+™ | CANINEBEAT® AI, an AI-based solution that helps detect heart murmurs in dogs and has already launched in the U.S., the UK and Germany. Boehringer Ingelheim also continues to support responses to emerging animal disease outbreaks, including New World screwworm in the U.S., after receiving Emergency Use Authorizations (EUAs) earlier this year from the U.S. Food and Drug Administration. The company continues to progress its R&D pipeline in Animal Health, with strong candidates across infectious and non-infectious diseases as well as parasiticides, building a solid innovation foundation for the future in pets, equine, and livestock animals. Outlook Looking ahead, Boehringer expects that uptake of recent launches, upcoming pipeline milestones, and ongoing investments in innovation will support performance for the remainder of the year and beyond. At the same time, the company will remain focused on navigating a dynamic external environment while maintaining a balanced and disciplined approach to growth. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at .

Phase 3Drug ApprovalVaccineClinical ResultImmunotherapy

28 Jan 2026

·endpoints.news

Boehringer Ingelheim takes rare kidney disease drug to Phase 3 despite puzzling mid-stage data

Boehringer Ingelheim’s experimental pill has shown signs of improving kidney function in patients with a rare renal condition in a mid-stage trial. But the data are somewhat confusing, with the lowest dose working better than two higher levels. Nonetheless, Boehringer has just begun a Phase 3 study. Data from the Phase 2 trial showed that the drug, called apecotrep, cut levels of protein in the urine of patients with a form of kidney damage known as primary focal segmental glomerulosclerosis (FSGS). The trial tested three doses of apecotrep. Its primary endpoint was proteinuria response, defined as a reduction of at least 25% in the urine protein creatinine ratio, which is a measure of kidney function. According to data from the study published in the Lancet , responses were seen in 44% of patients given 20 mg once-daily doses of apecotrep. In the 40 mg and 80 mg cohorts, 14% and 43% of subjects responded, respectively. The placebo group’s response rate was 7%. Patients given the lowest 20 mg dose had a placebo-adjusted reduction in proteinuria of 40% after three months of treatment, the company said Wednesday. The Lancet data show this was the dose with the strongest response on this measure, despite being the lowest. Patients given 40 mg and 80 mg of Boehringer’s drug had placebo-adjusted proteinuria reductions of just 5% and 23%, respectively. The Lancet paper authors suggested that the lack of a dose response “indicates that an efficacy plateau is likely being reached with the 20 mg dose.” They added that the 40 mg group had the fewest evaluable participants — just 10 — and the largest number of dropouts, “increasing the variability of observations in this group versus other groups.” According to the Lancet data, the drug was well tolerated, with no meaningful differences in side-effect rates between the treatment and placebo arms. Treatment-emergent adverse events were reported by 71% of subjects in both the apecotrep and placebo arms. Patients with FSGS have scar tissue and loss of podocytes, cells that line the glomerular filtration units of the kidney. This causes protein to leak into the urine rather than being absorbed by the body. FSGS can be secondary to an infection or diseases, including diabetes and lupus, but in primary FSGS, the cause is unknown. No approved disease-modifying therapy for FSGS currently exists. Boehringer’s drug, also known as BI 764198, is a potential first-in-class TRPC6 inhibitor. TRPC6 overactivity could be a cause of podocyte loss and kidney function decline. The drug is now in a placebo-controlled Phase 3 study, which is signing up adults and adolescents with primary FSGS. This will have the same primary endpoint, but will be assessed after two years of treatment. The record on the federal trials database does not list what dose or doses will be studied. Boehringer said it would also start a Phase 2 trial of other proteinuric kidney diseases, including secondary FSGS and Alport syndrome, in the first quarter of this year.

Phase 3Clinical ResultPhase 2

28 Jan 2026

·firstwordpharma.com

Hoping for clear-cut win, Boehringer starts pivotal study of FSGS drug

Boehringer Ingelheim has kicked off a Phase III study of the experimental TRPC6 inhibitor apecotrep (BI 764198) in people with primary focal segmental glomerulosclerosis (FSGS), despite the once-daily, oral therapy showing mixed results in an earlier trial. The company disclosed the start of the late-stage study on Wednesday, alongside supporting data published in The Lancet.Results from a Phase II trial showed that across all doses of apecotrep, proteinuria responses occurred in 35% of patients, compared to 7.1% for placebo. A treatment response was defined as a ≥25% reduction in urine protein-creatinine ratio (UPCR) after 12 weeks.The study randomised 62 participants aged 18-75 years with biopsy-confirmed primary FSGS or with a disease-causing TRPC6 variant to receive one of three doses of apecotrep or placebo.While the 20-mg dose of apecotrep was associated with a proteinuria response rate of 44%, the rate for the 40-mg dose was only 14%, with it rising for the 80-mg dose to 43%. Results also showed that in the 20-mg dose group, there was a 40% reduction in UPCR versus placebo.Boehringer said that apecotrep was well tolerated in the study, with rates of adverse events being 71% for both the drug and placebo.Despite the mixed signal for apecotrep, lead investigator Howard Trachtman said "these clinically relevant findings reinforce the importance of further investigation of its potential as a first-in-class targeted treatment for primary FSGS, where the unmet need remains high."Along with FSGS, Boehringer is investigating apecotrep in other proteinuric kidney diseases, with a Phase II trial set to start in the first quarter. The experimental drug is designed to protect podocytes from the excessive calcium entering cells — which is thought to be caused by overactivation of the TRPC6 protein — thus slowing down disease progression by decreasing proteinuria.

Phase 2Clinical ResultPhase 3

100 Deals associated with Apecotrep

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulosclerosis, Focal Segmental	Phase 3	United States	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	China	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Japan	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Argentina	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Australia	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Belgium	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Brazil	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Bulgaria	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Canada	Boehringer Ingelheim GmbH	16 Feb 2026
Glomerulosclerosis, Focal Segmental	Phase 3	Croatia	Boehringer Ingelheim GmbH	16 Feb 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05863130 (CTgov)	Phase 1	-	24	BI 764198 (Cohort 1: Classical hADME)	jcvsnqbgxs(clqeihlwef) = prszipyxzj waezeesbga (trmegxmgic, 6.23) View more	-	03 Jun 2026
				BI 764198 (Cohort 2: Microtracer hADME)	jcvsnqbgxs(clqeihlwef) = agpbxqagom waezeesbga (trmegxmgic, 6.04) View more
NCT05213624 (Pubmed \| Lancet)	Phase 2	Glomerulosclerosis, Focal Segmental	62	BI 764198 20 mg	akrvnkidos(dhtswjicyd) = ovhmxacare kqzkpgvnio (gpsgbarhvx ) View more	Positive	01 Feb 2026
				BI 764198 40 mg	akrvnkidos(dhtswjicyd) = fbqxiblfuz kqzkpgvnio (gpsgbarhvx ) View more
NCT05213624 (CTgov)	Phase 2	Glomerulosclerosis, Focal Segmental \| Chronic Kidney Diseases	67	BI 764198 (BI 764198 20 mg)	xscukwigyp = hgdvttzisg kvohzbnqwn (xysbiwzvzh, rxldlqbarr - locsbyvgoa) View more	-	12 Jan 2026
				BI 764198 (BI 764198 40 mg)	xscukwigyp = xnzeqfhrps kvohzbnqwn (xysbiwzvzh, yckdvrttir - abthnaazmf) View more
NCT05213624 (ASN2025)	Phase 2	Glomerulosclerosis, Focal Segmental	60	BI 764198	jfdjjuxozl(injzfdylwn) = ukjsmrbkty rktahyfzwg (kvhssmggsw )	Positive	08 Nov 2025
				BI 764198	jfdjjuxozl(injzfdylwn) = malysnlpnc rktahyfzwg (kvhssmggsw )
NCT04665700 (Pubmed \| Expert Opin Investig Drugs)	Phase 1	TRPC6	44	BI 764,198 20 mg	kzfdyzyybl(abrtbxgdhr) = ofxeinzmuw ablxszhqbr (ewcggpgqro ) View more	-	04 May 2025
				Placebo	kzfdyzyybl(abrtbxgdhr) = kfvszfronu ablxszhqbr (ewcggpgqro ) View more
NCT04102462 \| NCT03854552 \| NCT04176536 \| NCT04656288 (Phase 1 trials of BI 764198, Pubmed \| Expert Opin Investig Drugs)	Phase 1	Renal Insufficiency	54	BI 764198	ewlewmjwsi(zliwhuevhn) = 1 participant (16.7%) experienced diarrhea kozrhdyqpf (fzgxvsccxh ) View more	Positive	04 May 2025
				Placebo
NCT04604184 (Pubmed)	Phase 2	COVID-19	-	BI 764198	vgdujifcqi(lptwiktiwt): days = 3.41 (95% CI, 0.49 - 6.34) View more	Negative	06 Apr 2023
				Placebo
NCT04604184 (CTgov)	Phase 2	COVID-19 \| Respiratory Distress Syndrome, Acute	133	BI 764198 (BI 764198 Treatment Group)	rjzvmszwms = muexyiekcb zrhnbjqego (rththgbicb, eddkwcxyfi - lpdyykyznc) View more	-	11 Apr 2022
				Placebo (Placebo)	rjzvmszwms = gbqqbnxlod zrhnbjqego (rththgbicb, hepdcaumzo - nrqwtjetig) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis